Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as WNT974
LGK974 · 1 trial · 8 indications
DLT is defined as an adverse event or abnormal laboratory value that is assessed by the investigator as unrelated to disease, disease progression, intercurrent illness, or concomitant medications and that meets the criteria defined in the study protocol. The objective was to determine the Maximum Tolerated Dose (MTD) or Recommended Dose for Expansion (RDE) of LGK974 as a single agent and in combination with PDR001 when administered orally to adult patients with malignancies dependent on Wnt ligands.
| Arm | Type | Description |
|---|---|---|
| LGK974 | EXPERIMENTAL | LGK974 |
| LGK974 in combination with PDR001 | EXPERIMENTAL | LGK in combination with PDR001 |
| Name | Type | Description |
|---|---|---|
| LGK974 | DRUG | - |
| PDR001 | BIOLOGICAL | - |
Inclusion Criteria: Diagnosis of locally advanced or metastatic cancer that has progressed despite standard therapy or for which no effective standard therapy exists and histological confirmation of one of the following diseases indicated below: Single Agent Dose escalation part:documented B-RAF m...
Top 20 of 69 competitors
LGK974 is an investigational small molecule being studied in pancreatic cancer and other malignancies that depend on Wnt ligands. It has been evaluated in a Phase 1 trial that enrolled patients with pancreatic cancer, BRAF mutant colorectal cancer, melanoma, triple negative breast cancer, and several squamous cell cancers.
LGK974 targets malignancies dependent on Wnt ligands. The Phase 1 study was designed to evaluate LGK974 in patients whose tumors are driven by Wnt ligand signaling, and the trial included biomarker-selected patients.
LGK974 is being developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the Phase 1 clinical trial of LGK974 in patients with malignancies dependent on Wnt ligands.
LGK974 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The Phase 1 trial has been completed, and no active trials are currently listed for LGK974.
LGK974 has been studied in one Phase 1 clinical trial, NCT01351103, titled A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands. The trial enrolled 185 patients across the United States, Canada, France, Germany, Italy, Netherlands, and Spain, and it is now completed.